Using dupilumab to treat hair loss in children with alopecia areata
Official title: Dupilumab in the Treatment of Pediatric Alopecia Areata
Funded at Icahn School of Medicine at Mount Sinai · NIH-11089294 · Data updated 2026-11-12
This study is looking at how a medication called dupilumab can help kids with alopecia areata, a condition that causes hair loss, by encouraging hair regrowth and making sure the treatment is safe and effective for them.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 15, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $1,319,400 |
| NIH project number | 5U01AI179629-02 |
| Project ID | NIH-11089294 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children and adolescents diagnosed with alopecia areata, particularly those with atopic conditions or high levels of IgE.
✕Less likely to help
Patients who do not have alopecia areata or those with other forms of hair loss unrelated to immune responses may not benefit from this research.
What this research studies
This research investigates the use of dupilumab, a monoclonal antibody, to treat pediatric patients suffering from alopecia areata, a condition that causes hair loss. The study aims to understand how dupilumab can promote hair regrowth by targeting specific immune responses associated with the condition, particularly in children with atopic backgrounds. By enrolling pediatric patients, the research seeks to provide a safer and more effective treatment option for those with significant hair loss. Participants will be closely monitored to assess the effectiveness and safety of the treatment over the course of the study.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for children suffering from alopecia areata, potentially restoring their hair and improving their quality of life.
How similar studies have gone: Previous studies have shown promising results with dupilumab in adult patients with alopecia areata, suggesting potential success in pediatric populations as well.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Guttman, Emma — Icahn School of Medicine at Mount Sinai
- Study coordinator: Guttman, Emma
Related research
Other NIH-funded projects on the same topics.
-
Dupilumab for hair regrowth in children with alopecia areata
This project gives dupilumab to children and teens with widespread alopecia areata, especially those with allergies or high IgE, to help their hair grow back.
-
Targeting the NKG2A immune pathway to treat alopecia areata
This project will try blocking the NKG2A immune signal to reduce the immune attack on hair follicles and help people with alopecia areata regrow hair.
-
How IL-27 affects hair loss in alopecia areata
Researchers are exploring whether the immune molecule IL-27 helps stop the immune attack that causes hair loss in people with alopecia areata.
-
Using hydrogels to treat hair loss in alopecia areata
This study is exploring a new gel treatment for people with alopecia areata, a condition that causes hair loss, to see if it can help stimulate hair regrowth in a safe and effective way.
-
Investigating the NKG2A pathway to treat hair loss in alopecia areata
This study is looking at alopecia areata, a condition that causes hair loss, and is exploring new ways to help by targeting certain immune cells; if you're dealing with this condition, you might have a chance to join trials testing these exciting new treatments.
-
Investigating the role of IL-27 in hair loss caused by autoimmune disease
This study is looking at how a substance called IL-27 affects the immune system in people with alopecia areata, a condition that causes hair loss, to find new ways to help treat it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.